LIGAND PHARMS GENERAL CVR (LGNYZ) Net Income by Year
LIGAND PHARMS GENERAL CVR reported $124.5M in net income in fiscal year 2025. This represents an increase of 3186.6% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $197.2M in net income. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters LIGAND PHARMS GENERAL CVR has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
LGNYZ Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $197.2M | $124.5M+3186.6% | -$4.0M-107.7% | $52.2M+256.3% | -$33.4M-158.4% | $57.1M+2014.2% | -$3.0M-100.5% | $629.3M+339.1% | $143.3M+1041.5% | $12.6M+867.5% | -$1.6M-100.7% | $229.8M+1811.4% | $12.0M+5.3% | $11.4M+2267.0% | -$527K-105.4% | $9.7M |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
LGNYZ Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More LIGAND PHARMS GENERAL CVR financials
Frequently Asked Questions
What was LIGAND PHARMS GENERAL CVR's net income in fiscal year 2025?
LIGAND PHARMS GENERAL CVR reported $124.5M in net income in fiscal year 2025.
How fast is LIGAND PHARMS GENERAL CVR's net income growing?
LIGAND PHARMS GENERAL CVR (LGNYZ) net income rose by 3186.6% year over year, from -$4.0M to $124.5M in fiscal year 2025.
What is LIGAND PHARMS GENERAL CVR's net income over the last twelve months?
LIGAND PHARMS GENERAL CVR (LGNYZ) reported $197.2M in net income over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has LIGAND PHARMS GENERAL CVR's net income changed over the years?
Across the 15 fiscal years this page covers, LIGAND PHARMS GENERAL CVR (LGNYZ) net income went from $9.7M in fiscal year 2011 to $124.5M in fiscal year 2025.
What was LIGAND PHARMS GENERAL CVR's net income in the most recent quarter?
LIGAND PHARMS GENERAL CVR (LGNYZ) reported $48.5M in net income in Q2 2026. This represents an increase of 900.8% from the same quarter a year earlier.
What does net income mean on a financial statement?
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what LIGAND PHARMS GENERAL CVR (LGNYZ) reported on that line in every period on record.